STOCKWATCH: How to hide the meaning of clinical data
This article was originally published in Scrip
Investors like to be informed. So it is more than a little frustrating when public companies' clinical trial announcements omit important details; the way the trial was conducted, for instance, or the type of statistical analysis or the nature of the control with which a treatment was compared (scripintelligence.com, 16 July 2013).
You may also be interested in...
Novartis’s comparatively anemic revenue growth and Lilly’s sales shortfall suggest that hopes for an immediate sector recovery from the pandemic are premature.
Recovering pharmaceutical and medical device revenues at J&J hint at the green shoots germinating from the pandemic. Roche’s COVID-19 diagnostics revenue growth was its own green shoot, but can these be maintained as the pandemic evolves?
Contrasting first-quarter preannouncements from a DNA sequencing company and a molecular diagnostics company may, with other seasonal pressures, imply a comparatively weak first quarter for therapeutic drug companies.